{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:52:41Z","timestamp":1780919561399,"version":"3.54.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jfma.2024.01.015","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T20:50:48Z","timestamp":1705697448000},"page":"1124-1130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Risk of hepatocellular carcinoma after viral clearance achieved by DAA treatment"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5643-9472","authenticated-orcid":false,"given":"Shinya","family":"Maekawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jfma.2024.01.015_bib1","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series","volume":"73","author":"Pawlotsky","year":"2020","journal-title":"J Hepatol"},{"issue":"22","key":"10.1016\/j.jfma.2024.01.015_bib2","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.3748\/wjg.v26.i22.2931","article-title":"Liver-related effects of chronic hepatitis C antiviral treatment","volume":"26","author":"Laursen","year":"2020","journal-title":"World J Gastroenterol"},{"issue":"7","key":"10.1016\/j.jfma.2024.01.015_bib3","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/ajg.2017.123","article-title":"HCV genotype 6 increased the risk for hepatocellular carcinoma among asian patients with liver cirrhosis","volume":"112","author":"Lee","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.jfma.2024.01.015_bib4","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.27095","article-title":"HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of US Veterans with HCV","volume":"60","author":"Kanwal","year":"2014","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jfma.2024.01.015_bib5","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.21836","article-title":"Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis","volume":"46","author":"Akuta","year":"2007","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jfma.2024.01.015_bib6","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.510300409","article-title":"Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients","volume":"30","author":"Benhamou","year":"1999","journal-title":"The Multivirc Group. Hepatology."},{"issue":"6","key":"10.1016\/j.jfma.2024.01.015_bib7","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nrgastro.2014.17","article-title":"HCV and HIV co-infection: mechanisms and management","volume":"11","author":"Chen","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jfma.2024.01.015_bib8","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1053\/jhep.2001.29201","article-title":"The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study","volume":"34","author":"Di Martino","year":"2001","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jfma.2024.01.015_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0002-9270(00)02167-5","article-title":"Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C","volume":"96","author":"Garc\u00eca-Samaniego","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.jfma.2024.01.015_bib10","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1053\/j.gastro.2004.01.011","article-title":"Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection","volume":"126","author":"Liaw","year":"2004","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1016\/j.jfma.2024.01.015_bib11","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1002\/hep.1840360710","article-title":"Hepatocellular carcinoma and hepatitis C in the United States","volume":"36","author":"El-Serag","year":"2002","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jfma.2024.01.015_bib12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng.809","article-title":"Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma","volume":"43","author":"Kumar","year":"2011","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.jfma.2024.01.015_bib13","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/ng.876","article-title":"Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers","volume":"43","author":"Miki","year":"2011","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.jfma.2024.01.015_bib14","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jhep.2013.04.032","article-title":"Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma","volume":"59","author":"Lange","year":"2013","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jfma.2024.01.015_bib15","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/hep.24123","article-title":"Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C","volume":"53","author":"Valenti","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2024.01.015_bib16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40064-015-0870-5","article-title":"PNPLA3 I148M associations with liver carcinogenesis in Japanese chronic hepatitis C patients","volume":"4","author":"Nakaoka","year":"2015","journal-title":"SpringerPlus"},{"key":"10.1016\/j.jfma.2024.01.015_bib17","volume":"vol. 2010","author":"Chen","year":"2010"},{"issue":"2","key":"10.1016\/j.jfma.2024.01.015_bib18","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.cgh.2009.10.026","article-title":"Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus\u2013related cirrhosis","volume":"8","author":"Singal","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2024.01.015_bib19","doi-asserted-by":"crossref","first-page":"9954","DOI":"10.1038\/srep09954","article-title":"Systematic review: impact of interferon-based therapy on HCV-related hepatocellular carcinoma","volume":"5","author":"Hsu","year":"2015","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jfma.2024.01.015_bib20","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.28535","article-title":"Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection","volume":"64","author":"El-Serag","year":"2016","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jfma.2024.01.015_bib21","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.26442","article-title":"\u03b1\u2010fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C","volume":"58","author":"Asahina","year":"2013","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jfma.2024.01.015_bib22","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased risk for hepatocellular carcinoma persists up to 10 Years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores","volume":"157","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jfma.2024.01.015_bib23","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/hepr.12393","article-title":"Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon\u2010based antiviral therapy","volume":"45","author":"Hiramatsu","year":"2015","journal-title":"Hepatol Res"},{"issue":"4","key":"10.1016\/j.jfma.2024.01.015_bib24","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jfma.2024.01.015_bib25","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1053\/j.gastro.2016.12.021","article-title":"Unusually high rates of hepatocellular carcinoma after treatment with direct-acting antiviral therapy for hepatitis C related cirrhosis","volume":"152","author":"Ravi","year":"2017","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jfma.2024.01.015_bib26","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J Hepatol"},{"issue":"10179","key":"10.1016\/j.jfma.2024.01.015_bib27","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jfma.2024.01.015_bib28","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jfma.2024.01.015_bib29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12072-019-09933-8","article-title":"Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?","volume":"13","author":"Hanafy","year":"2019","journal-title":"Hepatol Int"},{"issue":"1","key":"10.1016\/j.jfma.2024.01.015_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","article-title":"HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma","volume":"68","author":"Ioannou","year":"2018","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jfma.2024.01.015_bib31","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jfma.2024.01.015_bib32","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jhep.2017.05.028","article-title":"Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C","volume":"67","author":"Nagata","year":"2017","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jfma.2024.01.015_bib33","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2018.07.015","article-title":"Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs","volume":"155","author":"Nahon","year":"2018","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.jfma.2024.01.015_bib34","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/apt.14593","article-title":"Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study","volume":"47","author":"Singer","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2024.01.015_bib35","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s12072-020-10105-2","article-title":"HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort","volume":"14","author":"Tanaka","year":"2020","journal-title":"Hepatology international"},{"issue":"2","key":"10.1016\/j.jfma.2024.01.015_bib36","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents","volume":"155","author":"Calvaruso","year":"2018","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jfma.2024.01.015_bib37","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jhep.2020.11.021","article-title":"Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity","volume":"74","author":"Krassenburg","year":"2021","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jfma.2024.01.015_bib38","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/ijc.30521","article-title":"Impact of sustained viral response postcurative therapy of hepatitis C-related hepatocellular carcinoma: a systematic review and meta-analysis","volume":"140","author":"Manthravadi","year":"2017","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.jfma.2024.01.015_bib39","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2018.09.029","article-title":"Impact of direct-acting antivirals on early recurrence of HCV-related HCC: comparison with interferon-based therapy","volume":"70","author":"Nishibatake Kinoshita","year":"2019","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.jfma.2024.01.015_bib40","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.3390\/jcm10081694","article-title":"Hepatocellular carcinoma recurrence after hepatitis C virus therapy with direct-acting antivirals. A systematic review and meta-analysis","volume":"10","author":"Frazzoni","year":"2021","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.jfma.2024.01.015_bib41","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2016.05.045","article-title":"Of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts","volume":"65","author":"Lack","year":"2016","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jfma.2024.01.015_bib42","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.01.027","article-title":"Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort study","volume":"156","author":"Singal","year":"2019","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jfma.2024.01.015_bib43","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/gutjnl-2020-323663","article-title":"Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis","volume":"71","author":"Sapena","year":"2022","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.jfma.2024.01.015_bib44","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jvh.12854","article-title":"Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: a comparative analysis","volume":"25","author":"El Kassas","year":"2018","journal-title":"J Viral Hepat"},{"issue":"8","key":"10.1016\/j.jfma.2024.01.015_bib45","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/liv.13357","article-title":"A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma","volume":"37","author":"Cabibbo","year":"2017","journal-title":"Liver Int"},{"issue":"7779","key":"10.1016\/j.jfma.2024.01.015_bib46","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s41586-019-1670-9","article-title":"Somatic mutations and clonal dynamics in healthy and cirrhotic human liver","volume":"574","author":"Brunner","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jfma.2024.01.015_bib47","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.09.025","article-title":"Leptin receptor somatic mutations are frequent in HCV-infected cirrhotic liver and associated with hepatocellular carcinoma","volume":"146","author":"Ikeda","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2024.01.015_bib48","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s00535-019-01555-z","article-title":"Comprehensive analysis of genetic aberrations linked to tumorigenesis in regenerative nodules of liver cirrhosis","volume":"54","author":"Kim","year":"2019","journal-title":"J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jfma.2024.01.015_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2019.03.026","article-title":"Somatic mutations increase hepatic clonal fitness and regeneration in chronic liver disease","volume":"177","author":"Zhu","year":"2019","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.jfma.2024.01.015_bib50","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jhep.2020.01.019","article-title":"The landscape of gene mutations in cirrhosis and hepatocellular carcinoma","volume":"72","author":"M\u00fcller","year":"2020","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jfma.2024.01.015_bib51","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/hep.22110","article-title":"Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma","volume":"47","author":"Nishida","year":"2008","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jfma.2024.01.015_bib52","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2013.10.056","article-title":"Hepatitis virus infection affects DNA methylation in mice with humanized livers","volume":"146","author":"Okamoto","year":"2014","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jfma.2024.01.015_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1008181","article-title":"Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals","volume":"15","author":"Perez","year":"2019","journal-title":"PLoS Genet"},{"issue":"8","key":"10.1016\/j.jfma.2024.01.015_bib54","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.02.038","article-title":"HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response","volume":"156","author":"Hamdane","year":"2019","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jfma.2024.01.015_bib55","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jhep.2022.08.042","article-title":"Reverse inflammaging: long-term effects of HCV cure on biological age","volume":"78","author":"Oltmanns","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jfma.2024.01.015_bib56","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1535370219898141","article-title":"Mechanisms of liver fibrosis and its role in liver cancer","volume":"245","author":"Dhar","year":"2020","journal-title":"Exp Biol Med (Maywood)"},{"issue":"7","key":"10.1016\/j.jfma.2024.01.015_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20071723","article-title":"The role of fibrosis and liver-associated fibroblasts in the pathogenesis of hepatocellular carcinoma","volume":"20","author":"Baglieri","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.jfma.2024.01.015_bib58","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/hep.24108","article-title":"Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells","volume":"53","author":"Schrader","year":"2011","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.jfma.2024.01.015_bib59","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3390\/cancers9090110","article-title":"Integrins as therapeutic targets: successes and cancers","volume":"9","author":"Raab-Westphal","year":"2017","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.jfma.2024.01.015_bib60","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cca.2022.09.022","article-title":"Serum biomarkers for liver fibrosis","volume":"537","author":"Chen","year":"2022","journal-title":"Clin Chim Acta"},{"issue":"4","key":"10.1016\/j.jfma.2024.01.015_bib61","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3892\/mco.2021.2377","article-title":"Enhanced liver fibrosis score as a predictive marker for hepatocellular carcinoma development after hepatitis C virus eradication","volume":"15","author":"Kawaguchi","year":"2021","journal-title":"Mol Clin Oncol"},{"issue":"3","key":"10.1016\/j.jfma.2024.01.015_bib62","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/hep.29911","article-title":"Liver angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after hepatitis C virus direct-acting antivirals","volume":"68","author":"Faillaci","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jfma.2024.01.015_bib63","article-title":"Serum angiopoietin-2 predicts the occurrence and recurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis","volume":"15","author":"Kawagishi","year":"2023","journal-title":"C. Viruses."},{"issue":"6","key":"10.1016\/j.jfma.2024.01.015_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179096","article-title":"On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C","volume":"12","author":"Chu","year":"2017","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jfma.2024.01.015_bib65","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1172\/JCI75938","article-title":"Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome","volume":"124","author":"Meissner","year":"2014","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.jfma.2024.01.015_bib66","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.10.035","article-title":"Levels of cytokines in serum associate with development of hepatocellular carcinoma in patients with HCV infection treated with direct-acting antivirals","volume":"154","author":"Debes","year":"2018","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jfma.2024.01.015_bib67","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/hepr.13861","article-title":"Significance of serum IP-10\/CXCL10 measurement in predicting post-direct acting antiviral treatment liver function in patients with HCV-decompensated liver cirrhosis","volume":"53","author":"Katoh","year":"2023","journal-title":"Hepatol Res"},{"issue":"6","key":"10.1016\/j.jfma.2024.01.015_bib68","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1002\/hep.30988","article-title":"Cure with interferon-free direct-acting antiviral is associated with increased survival in patients with hepatitis C virus-related hepatocellular carcinoma from both east and west","volume":"71","author":"Dang","year":"2020","journal-title":"Hepatology"},{"issue":"14","key":"10.1016\/j.jfma.2024.01.015_bib69","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.3390\/cancers13143455","article-title":"Characteristics and survival outcomes of hepatocellular carcinoma developed after HCV SVR","volume":"13","author":"Yeh","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.jfma.2024.01.015_bib70","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2019.03.027","article-title":"Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients","volume":"71","author":"Cabibbo","year":"2019","journal-title":"J Hepatol"},{"issue":"18","key":"10.1016\/j.jfma.2024.01.015_bib71","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.2169\/internalmedicine.8456-21","article-title":"The impact of antiviral therapy for hepatitis C virus on the survival of patients after hepatocellular carcinoma treatment","volume":"61","author":"Mori","year":"2022","journal-title":"Intern Med"},{"issue":"4","key":"10.1016\/j.jfma.2024.01.015_bib72","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.jhep.2022.04.028","article-title":"HCC prediction post SVR: many tools yet limited generalizability","volume":"77","author":"Bhagat","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jfma.2024.01.015_bib73","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/hep.32779","article-title":"Risk stratification and early detection biomarkers for precision HCC screening","volume":"78","author":"Lee","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jfma.2024.01.015_bib74","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jhep.2021.11.025","article-title":"HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease","volume":"76","author":"Semmler","year":"2022","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jfma.2024.01.015_bib75","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/hep4.1833","article-title":"Hepatocellular carcinoma risk assessment for patients with advanced fibrosis after eradication of hepatitis C virus","volume":"6","author":"Tamaki","year":"2022","journal-title":"Hepatol Commun"},{"issue":"9","key":"10.1016\/j.jfma.2024.01.015_bib76","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.15626","article-title":"Assessment of a deep learning model to predict hepatocellular carcinoma in patients with hepatitis C cirrhosis","volume":"3","author":"Ioannou","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.jfma.2024.01.015_bib77","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1002\/ijc.33245","article-title":"Liver cancer prediction in a viral hepatitis cohort: a deep learning approach","volume":"147","author":"Phan","year":"2020","journal-title":"Int J Cancer"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664624000482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664624000482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T07:23:42Z","timestamp":1739345022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664624000482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":77,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0929664624000482"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2024.01.015","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of hepatocellular carcinoma after viral clearance achieved by DAA treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2024.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}